TY - JOUR
T1 - Prophylactic antibiotics for massive endoprostheses in orthopaedic oncology: gaps in our understanding
AU - Azamgarhi, Tariq
AU - Warren, S.
AU - Fouch, Sarah
AU - Standing, J.
AU - Gerrand, C.
N1 - 12 month embargo
PY - 2023/8/1
Y1 - 2023/8/1
N2 - The recently published Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial found no benefit in extending antibiotic prophylaxis from 24 hours to five days after endoprosthetic reconstruction for lower limb bone tumours. PARITY is the first randomized controlled trial in orthopaedic oncology and is a huge step forward in understanding antibiotic prophylaxis. However, significant gaps remain, including questions around antibiotic choice, particularly in the UK, where cephalosporins are avoided due to concerns of Clostridioides difficile infection. We present a review of the evidence for antibiotic choice, dosing, and timing, and a brief description of PARITY, its implication for practice, and the remaining gaps in our understanding.
AB - The recently published Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial found no benefit in extending antibiotic prophylaxis from 24 hours to five days after endoprosthetic reconstruction for lower limb bone tumours. PARITY is the first randomized controlled trial in orthopaedic oncology and is a huge step forward in understanding antibiotic prophylaxis. However, significant gaps remain, including questions around antibiotic choice, particularly in the UK, where cephalosporins are avoided due to concerns of Clostridioides difficile infection. We present a review of the evidence for antibiotic choice, dosing, and timing, and a brief description of PARITY, its implication for practice, and the remaining gaps in our understanding.
UR - https://boneandjoint.org.uk/journal/BJJ/instructions-for-authors
U2 - 10.1302/0301-620X.105B8.BJJ-2022-1418.R1
DO - 10.1302/0301-620X.105B8.BJJ-2022-1418.R1
M3 - Article
SN - 2049-4394
VL - 105-B
SP - 850
EP - 856
JO - Bone and Joint Journal
JF - Bone and Joint Journal
IS - 8
ER -